PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.
19 octubre 2019
Eribulin . Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment .
Download PDF (3033K)
Pneumothorax has Been Reported as a Pazopanib
-Associated Adverse Event in Patients with Lung Metastases of Soft Tissue Sarcoma (STS).
However, Pneumothorax Triggered by Eribulin Treatment has Mever Been Reported.
We herein report two cases of spontaneous Pneumothorax in Patients with STS treated with Eribulin. Both Patients experienced Pneumothorax accompanied by sudden dyspnea on day 9 or 10 of Eribulin Treatment. These two cases suggest that spontaneous Pneumothorax may occur as an adverse event of Eribulin treatment in such Patients.
We should therefore be alert for the potential development of Pneumothorax during Eribulin Treatment of Patients with STS and Lung Metastases.
Suscribirse a:
Comentarios (Atom)


